Amylin Said to Draw First-Round Bids From Sanofi, Merck

Amylin Pharmaceuticals Inc., the diabetes drugmaker that has put itself up for sale, received offers from Sanofi and Merck & Co. in an initial round of bidding, said three people familiar with the process.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.